unknown
Stage
1
Investors
About
Angiex develops Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) to create targeted therapies for solid tumors by delivering chemotherapeutic agents directly to the nucleus of tumor and tumor blood vessel cells.
Explore Angiex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.